Overview
Targeted genomic profiling for AML, MDS and related myeloid neoplasms.
Why this Test Matters
Precision oncology depends on identifying clinically actionable genomic alterations. This assay helps clinicians select targeted therapies, evaluate immunotherapy eligibility, identify prognostic biomarkers, detect resistance mechanisms, and match patients to suitable clinical trials while minimizing sequential testing.
Who Should Consider this Test?
● AML ● MDS ● Disease progression ● Relapse
Applicable Cancer Types
AML, MDS, Myeloid neoplasms
What is Covered?
- 52 genes
- SNVs
- InDels
- Risk biomarkers
Clinical Utility
- Treatment selection
Prognostic and predictive biomarkers - Clinical trial matching
- Identification of actionable alterations
- Comprehensive clinical interpretation
Technology
Targeted myeloid sequencingkey Features
| Parameter | Details |
|---|---|
|
Sample Type |
Peripheral blood/Bone marrow |
|
Samples |
1 FFPE block or 10–15 slides |
|
Turnaround Time |
10–14 working days |
|
Report Includes |
Variant interpretation, therapy associations, clinically actionable biomarkers |
|
Quality |
High-depth NGS with rigorous QC |